Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide

Cardiovascular Research

Volumn 32, Issue 6, 1996, Pages 1071-1080

  Elliott, Gary T ^a   Comerford, Malissa L ^a   Smith, Jerry R ^a   Zhao, Lin ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

ATP sensitive; monophosphoryl lipid A; myocardial infarction; myocardial ischemia; potassium channel; preconditioning; rabbit, anesthetized; sulphonylureas

Indexed keywords

GLIBENCLAMIDE; LIPID A; PHOSPHORYL LIPID A; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; HYPOGLYCEMIA; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION;

ADENOSINE TRIPHOSPHATE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYBURIDE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIPID A; MALE; MYOCARDIAL INFARCTION; POTASSIUM CHANNEL BLOCKERS; RABBITS; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030460062     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00154-X     Document Type: Article

References (54)

1. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 74:1986;1124-1136.
2. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation. 82:1990;609-619.
3. Parratt JR. Protection of the heart by ischemic-preconditioning: mechanisms and possibilities for pharmacologic exploitation. TIPS. 15:1994;19-25.
4. Volovsek A, Subramanian R, Reboussin D. Effects of duration of ischemia during preconditioning on mechanical function, enzyme release and energy production in the isolated working rat heart. J Mol Cell Cardiol. 24:1992;1011-1019.
5. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 88:1993;1264-1272.
6. Tang XL, Qui Y, Sun JZ, Park SW, Bolli MR. Time-course of late preconditioning against myocardial stunning in conscious pigs. Circulation 1995;92(suppl):I-388.
7. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockage: preventing protective preconditioning depends on time of initiation. Am J Physiol. 265:1993;H504-H505.
8. Ytehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 266:1994;H1145-H1152.
9. Splechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 75:1994;586-590.
10. Gato M, Lui Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:1995;611-621.
11. Cavero I, Djellas Y, Guillon J-M. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther. 9:1995;245-255.
12. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol. 261:1991;H1675-H1686.
13. Yao Z, Gross GJ. The ATP-dependent potassium channel: an endogenous cardioprotective mechanism. J Cardiovasc Pharmacol. 24:((suppl 4)):1984;S28-S34.
14. ATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol. 264:1993;H495-H504.
15. D'Alonso AJ, Darbenzio RB, Parham CS, Grover GJ. Effects of intracoronary cromakalim on postischemic contractile function and action potential duration. Cardiovasc Res. 26:1992;1046-1053.
16. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release and neutrophil function in dogs. Circulation. 92:1995;1236-1245.
17. Gross G, Pieper G, Farber NL, Warltier D, Hardman H. Effects of nicorandil on coronary circulation and myocardial ischemia. Am J Cardiol. 63:1989;11J.
18. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res. 73:1993;1193-1201.
19. ATP channels in the mechanism of cardioprotective ischemic preconditioning. Circulation 1995;92(suppl):I-252.
20. Rohmann S, Weygandt H, Schelling P, Kie Soli L, Verdouw PD, Lues I. Involvement of ATP-sensitive potassium channels in preconditioning protection. Basic Res Cardiol. 89:1994;563-576.
21. Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J Pharmacol Exp Ther. 251:1989;98-104.
22. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 257:1982;11808-11815.
23. Takayama K, Qureshi N, Ribi E, Cantrell JL. Separation and characterization of toxic and nontoxic forms of lipid A's. Rev Infect Dis. 6:1984;439-443.
24. Yao Z, Auchampach JA, Pieper GM, Gross G. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovascular Res. 27:1993;832-838.
25. Yao Z, Rasmussen JL, Hirt JL, Mei DA, Pieper GM, Gross GJ. Effects of monophosphoryl lipid A on myocardial ischemia/reperfusion injury in dogs. J Cardiovascular Pharmacol. 22:1993;653-663.
26. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Monophosphoryl lipid A (MLA) is a `preconditioning-mimetic' in the canine model. Circulation 1995;92(suppl):I-388.
27. Yoshida K-I, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic `preconditioning' in rabbit hearts without concomitant expression of 70-kilodalton heat shock protein. J Mol Cell Cardiol. 27:1995;A164.
28. Yao Z, Elliott GT, Gross GJ. Monophosphoryl lipid A (MLA) preserves myocardial contractile function following multiple, brief periods of coronary occlusion in dogs. Pharmacol. 51:1995;152-159.
29. Abd-Elfattah AS, Guo J-H, El-Sigaby NR, Elliott GT. Intravenous administration of monophosphoryl lipid A (MLA) 24 hours before aortic cross-clamping attenuates myocardial stunning in dogs. J Mol Cell Cardiol. 27:1995;A49.
30. Nelson DW, Brown JM, Banerjee A, et al. Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery. 110:1991;365-369.
31. Zhao L, Kirsch CC, Hagen SR, Elliott GT. Preservation of global cardiac function in the rabbit following protracted ischemia/reperfusion using monophosphoryl lipid A. J Mol Cell Cardiol. 28:1996;197-208.
32. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol. 27:1995;223-229.
33. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channel prevents myocardial preconditioning in dogs. Circ Res. 70:1992;223-233.
34. Astiz ME, Rackow EC, Still JG, et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med. 23:1995;9-17.
35. Henricson BE, Benjamin WR, Vogel SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun. 58:1990;2429-2437.
36. Kiener PA, Marek F, Rodgers G, Lin P-F, Wau G, Desiderio J. Induction of tumor necrosis factor, INF-α and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 141:1988;870-874.
37. Eddy LJ, Goeddel DV, Wong GHW. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun. 184:1992;1056-1059.
38. Wong GHW, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 58:1989;923-931.
39. Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA. 86:1989;2516-2520.
40. (+) channel blockers inhibit tissue factor expression by human monocytic cells. Circ Res. 76:1995;16-20.
41. ATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res. 28:1994;1337-1341.
42. Schulz R, Post H, Sakka S, Wallbridge DR, Heusch G. Intraischemic preconditioning: increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion. Circ Res. 76:1995;942-950.
43. + channel blocker. Circulation. 90:1994;700-705.
44. (+) channels mediate the cardioprotective effect of monophosphoryl lipid A. Circulation 1995(suppl)92:I-388.
45. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 270:1994;681-689.
46. Pigott J, Garner T, Boone B, Chang JK, Hyman A, Lippton H. Adrenomedullin (ADM): an endogenous coronary (COR) vasodilator peptide. Circulation 1994;90(Pt 2):I-257.
47. Gato M, Lui Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:1995;611-621.
48. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 270:1994;681-689.
49. Hartman JC, Houshyar H, Leva SC, Wall TM. A role of nitric oxide in myocardial ischemic preconditioning. Circulation 1995:(Suppl 92)I-716.
50. Cameron JS, Kilber KKA, Barry H, Barron DN, Sodder VH. Nitric oxide activates ATP-sensitive potassium channels in hypertrophied ventricular myocytes. FASEB J. 10:1996;A65.
51. Parratt JR, Szekeres L. Delayed protection of the heart against ischemia. TIPS. 16:1995;351-355.
52. Luss H, Walkins SC, Freeswick PD, et al. Characterization of inducible nitric oxide synthase expression in endotoxemic rat cardiac myocytes in vivo and following cytokine exposure in vitro. J Mol Cell Cardiol. 27:1995;2015-2029.
53. Shindo T, Ikeda U, Ohkawa F, et al. Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res. 29:1995;813-819.
54. McKenna TM, Li S, Tao S. PKC mediates LPS and phorbol-induced cardiac cell nitric oxide synthase activity and hypocontractility. Am J Physiol. 269:1995;H1891-H1898.